Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

111
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
111
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

92
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
92
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

138
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
138
Preclinical Development: Overview01:28

Preclinical Development: Overview

5.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.5K
Vaccinations01:51

Vaccinations

49.6K
Overview
49.6K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

112
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
112

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A narrative review of COVID-19 epidemiology and mRNA vaccine impact in children <12 years during the omicron era (November 2021 - December 2025).

Expert review of vaccines·2026
Same author

Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial.

Pediatrics·2026
Same author

Characteristics of Young Children Hospitalized With Acute Respiratory Failure From Infection With Respiratory Syncytial Virus, SARS-CoV-2, or Both, November 2023-March 2024.

Open forum infectious diseases·2026
Same author

Respiratory syncytial virus mRNA vaccine-induced immunity and protection against subgroups A and B in mice.

ImmunoHorizons·2026
Same author

The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost.

Science translational medicine·2026
Same author

Respiratory Syncytial Virus Hospitalizations in Adults ≥50 Years of Age and Those with Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026

Related Experiment Video

Updated: Nov 27, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

11.0K

COVID-19 vaccine development: a pediatric perspective.

Satoshi Kamidani1, Christina A Rostad1,2, Evan J Anderson1,2,3

  • 1Department of Pediatrics, Emory University School of Medicine.

Current Opinion in Pediatrics
|December 5, 2020
PubMed
Summary

Children are at risk for severe COVID-19 and its social impacts. Pediatric clinical trials are crucial for developing a safe and effective coronavirus disease 2019 (COVID-19) vaccine for children.

More Related Videos

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.6K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.4K

Related Experiment Videos

Last Updated: Nov 27, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

11.0K
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
13:36

Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches

Published on: May 6, 2015

10.6K
Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
10:03

Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

Published on: August 1, 2013

17.4K

Area of Science:

  • Pediatric infectious diseases
  • Vaccinology
  • Public health

Background:

  • Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has led to significant global morbidity and mortality.
  • Children are susceptible to SARS-CoV-2 infection, severe disease, and indirect consequences like educational disruption.

Purpose of the Study:

  • To review the impact of COVID-19 on children.
  • To inform pediatricians about adult COVID-19 vaccine trials.
  • To emphasize the importance of pediatric COVID-19 vaccine trials and build confidence in regulatory processes.

Main Methods:

  • Review of existing literature on COVID-19 in children.
  • Analysis of ongoing adult COVID-19 vaccine clinical trials.
  • Discussion of ethical considerations for pediatric vaccine trials.

Main Results:

  • Children face risks from SARS-CoV-2 infection and associated societal disruptions.
  • Adult vaccine trials show promising safety and efficacy.
  • Pediatric involvement in trials should parallel adult trials, ensuring careful, transparent processes.

Conclusions:

  • Pediatric COVID-19 vaccination offers direct and indirect benefits.
  • Inclusion of children in vaccine trials is essential for equitable access and public health.
  • Methodical and transparent trial processes are key to establishing vaccine confidence in pediatric populations.